Page 108 - 《中国药房》2023年23期

参考文献 patients with chronic immune thrombocytopenia[J]. Curr
[ 1 ] AUDIA S，MAHÉVAS M，SAMSON M，et al. Pathogene- Med Res Opin，2012，28（1）：79-87.
sis of immune thrombocytopenia[J]. Autoimmun Rev， [12] NEUMANN A，ŽIŽKA Z，KOUCKÝ M，et al. Fetal and
2017，16（6）：620-632. neonatal alloimmune thrombocytopenia[J]. Ceska Gyne‐
[ 2 ] KHELLAF M，VIALLARD J F，HAMIDOU M，et al. A kol，2018，83（6）：448-451.
retrospective pilot evaluation of switching thrombopoietic [13] LEE J Y，LEE J H，LEE H，et al. Epidemiology and ma-
receptor-agonists in immune thrombocytopenia[J]. Haema‐ nagement of primary immune thrombocytopenia：a nation‐
tologica，2013，98（6）：881-887. wide population-based study in Korea[J]. Thromb Res，
[ 3 ] KIM Y K，LEE S S，JEONG S H，et al. Efficacy and 2017，155：86-91.
safety of eltrombopag in adult refractory immune throm‐ [14] MOULIS G，PALMARO A，MONTASTRUC J L，et al.
bocytopenia[J]. Blood Res，2015，50（1）：19-25. Epidemiology of incident immune thrombocytopenia：a
[ 4 ] PARK R. Eltrombopag：a new treatment option for nationwide population-based study in France[J]. Blood，
chronic refractory adult immune thrombocytopenia[J]. 2014，124（22）：3308-3315.
Blood Res，2015，50（1）：1-2. [15] BASCIANO P A，BUSSEL J B. Thrombopoietin-receptor
[ 5 ] SYED Y Y. Hetrombopag：first approval[J]. Drugs，2021， agonists[J]. Curr Opin Hematol，2012，19（5）：392-398.
81（13）：1581-1585. [16] GHANIMA W，COOPER N，RODEGHIERO F，et al.
[ 6 ] WANG Z L，CHEN L，ZHANG F K，et al. First-in-patient Thrombopoietin receptor agonists：ten years later[J]. Hae‐
study of hetrombopag in patients with chronic idiopathic matologica，2019，104（6）：1112-1123.
thrombocytopenic purpura[J]. J Thromb Haemost，2020， [17] PENG G X，HE G S，CHANG H，et al. A multicenter
18（11）：3053-3060. phase Ⅱ study on the efficacy and safety of hetrombopag
[ 7 ] ZHENG L，LIANG M Z，ZENG X L，et al. Safety，phar‐ in patients with severe aplastic anemia refractory to immu‐
macokinetics and pharmacodynamics of hetrombopag nosuppressive therapy[J]. Ther Adv Hematol，2022，13：
olamine，a novel TPO-R agonist，in healthy individuals[J]. 20406207221085197.
Basic Clin Pharmacol Toxicol，2017，121（5）：414-422. [18] MEI H，LIU X F，LI Y，et al. A multicenter，randomized
[ 8 ] XIE C Y，ZHAO H J，BAO X B，et al. Pharmacological phase Ⅲ trial of hetrombopag：a novel thrombopoietin re‐
characterization of hetrombopag，a novel orally active hu‐ ceptor agonist for the treatment of immune thrombocyto‐
man thrombopoietin receptor agonist[J]. J Cell Mol Med， penia[J]. J Hematol Oncol，2021，14（1）：37.
2018，22（11）：5367-5377. [19] WINER E S，SAFRAN H，KARASZEWSKA B，et al. El‐
[ 9 ] 中华医学会血液学分会血栓与止血学组. 成人原发免疫 trombopag for thrombocytopenia in patients with ad‐
性血小板减少症诊断与治疗中国指南：2020年版[J]. 中 vanced solid tumors receiving gemcitabine-based chemo‐
华血液学杂志，2020，41（8）：617-623. therapy：a randomized，placebo-controlled phase 2 study
Thrombosis and Hemostasis Group，Branch Hematology， [J]. Int J Hematol，2017，106（6）：765-776.
Chinese Medical Association. Chinese guideline on the [20] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤协会
diagnosis and management of adult primary immune （CSCO）肿瘤治疗所致血小板减少症诊疗指南：2023
thrombocytopenia：version 2020[J]. Chin J Hematol， [M].北京：人民卫生出版社，2023：20，38.
2020，41（8）：617-623. Guidelines Working Committee of the Chinese Clinical
Oncology Society. Chinese Clinical Oncology Association
[10] PUAVILAI T，THADANIPON K，RATTANASIRI S，
et al. Treatment efficacy for adult persistent immune （CSCO） guidelines for the diagnosis and treatment of
thrombocytopenia caused by tumor therapy：2023[M].
thrombocytopenia：a systematic review and network meta-
Beijing：People’s Health Publishing House，2023：20，38.
analysis[J]. Br J Haematol，2020，188（3）：450-459.
（收稿日期：2023-05-06 修回日期：2023-11-15）
[11] FOGARTY P F，TARANTINO M D，BRAINSKY A，
（编辑：胡晓霖）
et al. Selective validation of the WHO Bleeding Scale in

· 2914 · China Pharmacy 2023 Vol. 34 No. 23 中国药房 2023年第34卷第23期